• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CDC Surveillance Week 22

H

HenryN

Retired
<TABLE border=1><CAPTION>INFLUENZA VIRUSES ISOLATED BY
WHO/NREVSS Collaborating Laboratories
2008 - 2009 Season
</CAPTION><TBODY><TR><TH id=header1 width=70>Week</TH><TH id=header2 width=90>A(H1)</TH><TH id=header3 width=70>A(Novel H1N1)</TH><TH id=header4 width=70>A(H3)</TH><TH id=header5 width=70>A(Could Not Subtyped)</TH><TH id=header6 width=70>A(Unk)</TH><TH id=header7 width=70>B </TH><TH id=header8 align=right>Total # Tested</TH><TH id=header9 align=right>% Positive</TH></TR><TR><TD headers=header1 align=right>40 </TD><TD headers=header2 align=right>3 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>0 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>8 </TD><TD headers=header7 align=right>6 </TD><TD headers=header8 align=right>2606 </TD><TD headers=header9 align=right>0.65 </TD></TR><TR><TD headers=header1 align=right>41 </TD><TD headers=header2 align=right>5 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>4 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>8 </TD><TD headers=header7 align=right>6 </TD><TD headers=header8 align=right>2635 </TD><TD headers=header9 align=right>0.87 </TD></TR><TR><TD headers=header1 align=right>42 </TD><TD headers=header2 align=right>13 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>3 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>15 </TD><TD headers=header7 align=right>6 </TD><TD headers=header8 align=right>2747 </TD><TD headers=header9 align=right>1.35 </TD></TR><TR><TD headers=header1 align=right>43 </TD><TD headers=header2 align=right>22 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>0 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>24 </TD><TD headers=header7 align=right>14 </TD><TD headers=header8 align=right>3198 </TD><TD headers=header9 align=right>1.88 </TD></TR><TR><TD headers=header1 align=right>44 </TD><TD headers=header2 align=right>12 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>3 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>21 </TD><TD headers=header7 align=right>5 </TD><TD headers=header8 align=right>3320 </TD><TD headers=header9 align=right>1.23 </TD></TR><TR><TD headers=header1 align=right>45 </TD><TD headers=header2 align=right>32 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>2 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>23 </TD><TD headers=header7 align=right>11 </TD><TD headers=header8 align=right>3922 </TD><TD headers=header9 align=right>1.73 </TD></TR><TR><TD headers=header1 align=right>46 </TD><TD headers=header2 align=right>25 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>2 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>23 </TD><TD headers=header7 align=right>12 </TD><TD headers=header8 align=right>4146 </TD><TD headers=header9 align=right>1.5 </TD></TR><TR><TD headers=header1 align=right>47 </TD><TD headers=header2 align=right>27 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>1 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>31 </TD><TD headers=header7 align=right>23 </TD><TD headers=header8 align=right>4541 </TD><TD headers=header9 align=right>1.81 </TD></TR><TR><TD headers=header1 align=right>48 </TD><TD headers=header2 align=right>40 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>1 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>47 </TD><TD headers=header7 align=right>24 </TD><TD headers=header8 align=right>4636 </TD><TD headers=header9 align=right>2.42 </TD></TR><TR><TD headers=header1 align=right>49 </TD><TD headers=header2 align=right>43 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>6 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>57 </TD><TD headers=header7 align=right>14 </TD><TD headers=header8 align=right>5356 </TD><TD headers=header9 align=right>2.24 </TD></TR><TR><TD headers=header1 align=right>50 </TD><TD headers=header2 align=right>71 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>9 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>66 </TD><TD headers=header7 align=right>37 </TD><TD headers=header8 align=right>5788 </TD><TD headers=header9 align=right>3.16 </TD></TR><TR><TD headers=header1 align=right>51 </TD><TD headers=header2 align=right>73 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>19 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>108 </TD><TD headers=header7 align=right>56 </TD><TD headers=header8 align=right>6057 </TD><TD headers=header9 align=right>4.23 </TD></TR><TR><TD headers=header1 align=right>52 </TD><TD headers=header2 align=right>71 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>12 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>153 </TD><TD headers=header7 align=right>51 </TD><TD headers=header8 align=right>5830 </TD><TD headers=header9 align=right>4.92 </TD></TR><TR><TD headers=header1 align=right>53 </TD><TD headers=header2 align=right>115 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>19 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>171 </TD><TD headers=header7 align=right>48 </TD><TD headers=header8 align=right>6314 </TD><TD headers=header9 align=right>5.59 </TD></TR><TR><TD headers=header1 align=right>01 </TD><TD headers=header2 align=right>165 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>27 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>285 </TD><TD headers=header7 align=right>83 </TD><TD headers=header8 align=right>6702 </TD><TD headers=header9 align=right>8.36 </TD></TR><TR><TD headers=header1 align=right>02 </TD><TD headers=header2 align=right>199 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>22 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>423 </TD><TD headers=header7 align=right>97 </TD><TD headers=header8 align=right>6831 </TD><TD headers=header9 align=right>10.85 </TD></TR><TR><TD headers=header1 align=right>03 </TD><TD headers=header2 align=right>349 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>44 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>623 </TD><TD headers=header7 align=right>186 </TD><TD headers=header8 align=right>7609 </TD><TD headers=header9 align=right>15.8 </TD></TR><TR><TD headers=header1 align=right>04 </TD><TD headers=header2 align=right>559 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>78 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>898 </TD><TD headers=header7 align=right>359 </TD><TD headers=header8 align=right>9017 </TD><TD headers=header9 align=right>21 </TD></TR><TR><TD headers=header1 align=right>05 </TD><TD headers=header2 align=right>675 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>52 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>1359 </TD><TD headers=header7 align=right>673 </TD><TD headers=header8 align=right>11467 </TD><TD headers=header9 align=right>24.06 </TD></TR><TR><TD headers=header1 align=right>06 </TD><TD headers=header2 align=right>816 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>63 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>1367 </TD><TD headers=header7 align=right>916 </TD><TD headers=header8 align=right>12593 </TD><TD headers=header9 align=right>25.11 </TD></TR><TR><TD headers=header1 align=right>07 </TD><TD headers=header2 align=right>819 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>65 </TD><TD headers=header5 align=right>1 </TD><TD headers=header6 align=right>1068 </TD><TD headers=header7 align=right>894 </TD><TD headers=header8 align=right>11503 </TD><TD headers=header9 align=right>24.75 </TD></TR><TR><TD headers=header1 align=right>08 </TD><TD headers=header2 align=right>678 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>59 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>1002 </TD><TD headers=header7 align=right>1098 </TD><TD headers=header8 align=right>11730 </TD><TD headers=header9 align=right>24.19 </TD></TR><TR><TD headers=header1 align=right>09 </TD><TD headers=header2 align=right>537 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>58 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>883 </TD><TD headers=header7 align=right>1089 </TD><TD headers=header8 align=right>10500 </TD><TD headers=header9 align=right>24.45 </TD></TR><TR><TD headers=header1 align=right>10 </TD><TD headers=header2 align=right>373 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>63 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>636 </TD><TD headers=header7 align=right>1002 </TD><TD headers=header8 align=right>9269 </TD><TD headers=header9 align=right>22.38 </TD></TR><TR><TD headers=header1 align=right>11 </TD><TD headers=header2 align=right>354 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>63 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>425 </TD><TD headers=header7 align=right>874 </TD><TD headers=header8 align=right>8304 </TD><TD headers=header9 align=right>20.66 </TD></TR><TR><TD headers=header1 align=right>12 </TD><TD headers=header2 align=right>258 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>41 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>281 </TD><TD headers=header7 align=right>604 </TD><TD headers=header8 align=right>7017 </TD><TD headers=header9 align=right>16.87 </TD></TR><TR><TD headers=header1 align=right>13 </TD><TD headers=header2 align=right>109 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>26 </TD><TD headers=header5 align=right>0 </TD><TD headers=header6 align=right>166 </TD><TD headers=header7 align=right>434 </TD><TD headers=header8 align=right>5423 </TD><TD headers=header9 align=right>13.55 </TD></TR><TR><TD headers=header1 align=right>14 </TD><TD headers=header2 align=right>88 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>31 </TD><TD headers=header5 align=right>1 </TD><TD headers=header6 align=right>125 </TD><TD headers=header7 align=right>259 </TD><TD headers=header8 align=right>4805 </TD><TD headers=header9 align=right>10.49 </TD></TR><TR><TD headers=header1 align=right>15 </TD><TD headers=header2 align=right>37 </TD><TD headers=header3 align=right>0 </TD><TD headers=header4 align=right>28 </TD><TD headers=header5 align=right>1 </TD><TD headers=header6 align=right>73 </TD><TD headers=header7 align=right>167 </TD><TD headers=header8 align=right>4240 </TD><TD headers=header9 align=right>7.22 </TD></TR><TR><TD headers=header1 align=right>16 </TD><TD headers=header2 align=right>40 </TD><TD headers=header3 align=right>13 </TD><TD headers=header4 align=right>31 </TD><TD headers=header5 align=right>3 </TD><TD headers=header6 align=right>79 </TD><TD headers=header7 align=right>98 </TD><TD headers=header8 align=right>3783 </TD><TD headers=header9 align=right>6.98 </TD></TR><TR><TD headers=header1 align=right>17 </TD><TD headers=header2 align=right>524 </TD><TD headers=header3 align=right>862 </TD><TD headers=header4 align=right>588 </TD><TD headers=header5 align=right>180 </TD><TD headers=header6 align=right>368 </TD><TD headers=header7 align=right>619 </TD><TD headers=header8 align=right>23929 </TD><TD headers=header9 align=right>13.13 </TD></TR><TR><TD headers=header1 align=right>18 </TD><TD headers=header2 align=right>365 </TD><TD headers=header3 align=right>1390 </TD><TD headers=header4 align=right>390 </TD><TD headers=header5 align=right>123 </TD><TD headers=header6 align=right>801 </TD><TD headers=header7 align=right>355 </TD><TD headers=header8 align=right>23046 </TD><TD headers=header9 align=right>14.86 </TD></TR><TR><TD headers=header1 align=right>19 </TD><TD headers=header2 align=right>94 </TD><TD headers=header3 align=right>1052 </TD><TD headers=header4 align=right>116 </TD><TD headers=header5 align=right>43 </TD><TD headers=header6 align=right>384 </TD><TD headers=header7 align=right>94 </TD><TD headers=header8 align=right>11202 </TD><TD headers=header9 align=right>15.92 </TD></TR><TR><TD headers=header1 align=right>20 </TD><TD headers=header2 align=right>39 </TD><TD headers=header3 align=right>1851 </TD><TD headers=header4 align=right>94 </TD><TD headers=header5 align=right>129 </TD><TD headers=header6 align=right>222 </TD><TD headers=header7 align=right>50 </TD><TD headers=header8 align=right>10166 </TD><TD headers=header9 align=right>23.47 </TD></TR><TR><TD headers=header1 align=right>21 </TD><TD headers=header2 align=right>11 </TD><TD headers=header3 align=right>1900 </TD><TD headers=header4 align=right>46 </TD><TD headers=header5 align=right>156 </TD><TD headers=header6 align=right>360 </TD><TD headers=header7 align=right>21 </TD><TD headers=header8 align=right>8380 </TD><TD headers=header9 align=right>29.76 </TD></TR><TR><TD headers=header1 align=right>22 </TD><TD headers=header2 align=right>9 </TD><TD headers=header3 align=right>2071 </TD><TD headers=header4 align=right>22 </TD><TD headers=header5 align=right>315 </TD><TD headers=header6 align=right>246 </TD><TD headers=header7 align=right>18 </TD><TD headers=header8 align=right>6664 </TD><TD headers=header9 align=right>40.23 </TD></TR></TBODY></TABLE>
http://cdc.gov/flu/weekly/index.htm
 
Re: CDC Surveillance Week 22

% positive going through the roof. In last week (#22), the level is above 40% (compared to a peak of 25% at the height of flu season in February).
 
Re: CDC Surveillance Week 22

2008-2009 Influenza Season Week 22 ending June 6, 2009
All data are preliminary and may change as more reports are received.

Synopsis:

During week 22 (May 31 ? June 6, 2009), influenza activity decreased in the United States, however, there are still higher levels of influenza-like illness than is normal for this time of year.
  • Two thousand six hundred eighty-one (40.2%) specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive for influenza.
  • Approximately 89% of all influenza viruses being reported to CDC were novel influenza A (H1N1) viruses.
  • The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.
  • Three influenza-associated pediatric deaths were reported; two were associated with novel influenza A (H1N1) virus infection and one was associated with seasonal influenza A (H1N1) virus infection.
  • The proportion of outpatient visits for influenza-like illness (ILI) was below the national baseline. Two of the 10 surveillance regions reported ILI above their region-specific baseline.
  • Eight states reported geographically widespread influenza activity, nine states reported regional influenza activity, the District of Columbia, Puerto Rico, and 15 states reported local influenza activity, 17 states reported sporadic influenza activity, and one state did not report.
<TABLE class=table border=0 cellSpacing=0 cellPadding=3 align=center><CAPTION>National and Regional Summary of Select Surveillance Components

</CAPTION><TBODY><TR vAlign=top><TH vAlign=bottom rowSpan=2 width=85>
HHS Surveillance Regions*​
</TH><TH width=260 colSpan=3 noWrap align=middle>Data for current week</STRONG></TH><TH width=280 colSpan=7 noWrap align=middle>Data cumulative for the season</TH></TR><TR vAlign=center><TH width=72 align=middle>Out-patient ILI?</TH><TH width=70 align=middle>% positive for flu?</TH><TH width=75 align=middle>Number of jurisdictions reporting regional or widespread activity?</TH><TH width=58 noWrap align=middle>A (H1)</TH><TH width=58 noWrap align=middle>A (H3)</TH><TH width=58 noWrap align=middle>Novel A (H1N1)</TH><TH width=58 noWrap align=middle>A (could not be subyped)?</TH><TH width=60 align=middle>A(Unsub-typed)</TH><TH width=55 noWrap align=middle>B</TH><TH width=55 align=middle>Pediatric Deaths</TH></TR><TR><TD width=85 align=left>Nation</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>40.2 % </TD><TD width=75 noWrap align=middle>17 of 52</TD><TD width=58 noWrap align=middle>7,650</TD><TD width=58 noWrap align=middle>2,088</TD><TD width=58 noWrap align=middle>9,139</TD><TD width=58 noWrap align=middle>952</TD><TD width=60 noWrap align=middle>12,829</TD><TD width=55 noWrap align=middle>10,303</TD><TD width=55 noWrap align=middle>70</TD></TR><TR><TD width=85 align=left>Region I</TD><TD width=72 noWrap align=middle>Elevated</TD><TD width=72 noWrap align=middle>34.5 % </TD><TD width=75 noWrap align=middle>4 of 6</TD><TD width=58 noWrap align=middle>520</TD><TD width=58 noWrap align=middle>151</TD><TD width=58 noWrap align=middle>1,232</TD><TD width=58 noWrap align=middle>13</TD><TD width=60 noWrap align=middle>1,173</TD><TD width=55 noWrap align=middle>800</TD><TD width=55 noWrap align=middle>1</TD></TR><TR><TD width=85 align=left>Region II</TD><TD width=72 noWrap align=middle>Elevated</TD><TD width=72 noWrap align=middle>31.1 % </TD><TD width=75 noWrap align=middle>2 of 3</TD><TD width=58 noWrap align=middle>277</TD><TD width=58 noWrap align=middle>135</TD><TD width=58 noWrap align=middle>467</TD><TD width=58 noWrap align=middle>16</TD><TD width=60 noWrap align=middle>1,339</TD><TD width=55 noWrap align=middle>710</TD><TD width=55 noWrap align=middle>9</TD></TR><TR><TD width=85 align=left>Region III</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>50.8 % </TD><TD width=75 noWrap align=middle>3 of 6</TD><TD width=58 noWrap align=middle>1,237</TD><TD width=58 noWrap align=middle>204</TD><TD width=58 noWrap align=middle>815</TD><TD width=58 noWrap align=middle>558</TD><TD width=60 noWrap align=middle>644</TD><TD width=55 noWrap align=middle>1,359</TD><TD width=55 noWrap align=middle>9</TD></TR><TR><TD width=85 align=left>Region IV</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>13.0 % </TD><TD width=75 noWrap align=middle>2 of 8</TD><TD width=58 noWrap align=middle>828</TD><TD width=58 noWrap align=middle>117</TD><TD width=58 noWrap align=middle>211</TD><TD width=58 noWrap align=middle>37</TD><TD width=60 noWrap align=middle>1,791</TD><TD width=55 noWrap align=middle>1,202</TD><TD width=55 noWrap align=middle>6</TD></TR><TR><TD width=85 align=left>Region V</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>44.6 % </TD><TD width=75 noWrap align=middle>1 of 6</TD><TD width=58 noWrap align=middle>1,653</TD><TD width=58 noWrap align=middle>183</TD><TD width=58 noWrap align=middle>4,322</TD><TD width=58 noWrap align=middle>123</TD><TD width=60 noWrap align=middle>526</TD><TD width=55 noWrap align=middle>1,305</TD><TD width=55 noWrap align=middle>11</TD></TR><TR><TD width=85 align=left>Region VI</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>14.5 % </TD><TD width=75 noWrap align=middle>1 of 5</TD><TD width=58 noWrap align=middle>748</TD><TD width=58 noWrap align=middle>145</TD><TD width=58 noWrap align=middle>701</TD><TD width=58 noWrap align=middle>5</TD><TD width=60 noWrap align=middle>4,058</TD><TD width=55 noWrap align=middle>2,583</TD><TD width=55 noWrap align=middle>14</TD></TR><TR><TD width=85 align=left>Region VII</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>10.9 % </TD><TD width=75 noWrap align=middle>0 of 4</TD><TD width=58 noWrap align=middle>497</TD><TD width=58 noWrap align=middle>59</TD><TD width=58 noWrap align=middle>145</TD><TD width=58 noWrap align=middle>98</TD><TD width=60 noWrap align=middle>446</TD><TD width=55 noWrap align=middle>529</TD><TD width=55 noWrap align=middle>0</TD></TR><TR><TD width=85 align=left>Region VIII</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>23.9 % </TD><TD width=75 noWrap align=middle>1 of 6</TD><TD width=58 noWrap align=middle>471</TD><TD width=58 noWrap align=middle>211</TD><TD width=58 noWrap align=middle>679</TD><TD width=58 noWrap align=middle>57</TD><TD width=60 noWrap align=middle>1,489</TD><TD width=55 noWrap align=middle>493</TD><TD width=55 noWrap align=middle>6</TD></TR><TR><TD width=85 align=left>Region IX</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>10.4 % </TD><TD width=75 noWrap align=middle>3 of 4</TD><TD width=58 noWrap align=middle>1,045</TD><TD width=58 noWrap align=middle>600</TD><TD width=58 noWrap align=middle>390</TD><TD width=58 noWrap align=middle>13</TD><TD width=60 noWrap align=middle>1,027</TD><TD width=55 noWrap align=middle>658</TD><TD width=55 noWrap align=middle>13</TD></TR><TR><TD width=85 align=left>Region X</TD><TD width=72 noWrap align=middle>Normal</TD><TD width=72 noWrap align=middle>20.9 % </TD><TD width=75 noWrap align=middle>0 of 4</TD><TD width=58 noWrap align=middle>374</TD><TD width=58 noWrap align=middle>283</TD><TD width=58 noWrap align=middle>177</TD><TD width=58 noWrap align=middle>32</TD><TD width=60 noWrap align=middle>336</TD><TD width=55 noWrap align=middle>664</TD><TD width=55 noWrap align=middle>1</TD></TR></TBODY></TABLE>
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and Region X: AK, ID, OR, WA)
? Elevated means the % of visits for ILI is at or above the national or region-specific baseline
? National data are for current week; regional data are for the most recent three weeks
? Includes all 50 states, the District of Columbia, and Puerto Rico
? The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further testing
U.S. Virologic Surveillance:

WHO and NREVSS collaborating laboratories located in all 50 states and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United States. On April 15 and 17, 2009, CDC confirmed the first two cases novel influenza A (H1N1) virus in the United States. As of June 12, 2009, 17,855 confirmed and probable infections with novel influenza A (H1N1) virus have been identified by CDC and state and local public health departments. Reporting of novel influenza A (H1N1) viruses by U.S. WHO collaborating laboratories began during week 17 (week ending May 2, 2009). The results of tests performed during the current week are summarized in the table below.
<TABLE class=table border=0 cellSpacing=0 cellPadding=2 align=center><TBODY><TR><TH width=225 align=left></TH><TH width=150 noWrap align=middle>Week 22</TH></TR><TR><TD width=225 align=left>No. of specimens tested</TD><TD width=150 noWrap align=middle>6,664</TD></TR><TR><TD width=225 align=left>No. of positive specimens (%)</TD><TD width=150 noWrap align=middle>2,681 (40.2%)</TD></TR><TR><TD colSpan=2 align=left>Positive specimens by type/subtype</TD></TR><TR><TD width=225 align=left> Influenza A</TD><TD width=150 noWrap align=middle>2,663 (99.3%)</TD></TR><TR><TD width=225 align=left> A (H1)</TD><TD width=150 noWrap align=middle> 9 (0.3%)</TD></TR><TR><TD width=225 align=left> A (H3)</TD><TD width=150 noWrap align=middle> 22 (0.8%)</TD></TR><TR><TD width=225 align=left> A (unsubtyped)</TD><TD width=150 noWrap align=middle> 246 (9.2%)</TD></TR><TR><TD width=225 align=left> A (could not be subtyped)</TD><TD width=150 noWrap align=middle> 315 (11.8%)</TD></TR><TR><TD width=225 align=left> A (novel influenza H1N1)</TD><TD width=150 noWrap align=middle> 2,071 (77.8%)</TD></TR><TR><TD width=220 align=left> Influenza B</TD><TD width=150 noWrap align=middle>18 (0.7%)</TD></TR></TBODY></TABLE>
During week 22, seasonal influenza A (H1), A (H3), and B viruses co-circulated at low levels with novel influenza A (H1N1). Approximately 89% of all influenza viruses being reported to CDC this week are novel influenza A (H1N1) viruses.
The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS collaborating laboratories may be due in part to changes in testing practices by health care providers, triaging of specimens by public health laboratories, an increase in the number of specimens collected from outbreaks, and other factors.


<CENTER>
image221.gif

View WHO-NREVSS Regional Bar Charts| View Chart Data | View Full Screen </CENTER>Antigenic Characterization:

CDC has antigenically characterized 1,626 seasonal human influenza viruses [947 influenza A (H1), 162 influenza A (H3) and 517 influenza B viruses] collected by U.S. laboratories since October 1, 2008, and 125 novel influenza A (H1N1) viruses.
All 947 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 2008-09 influenza vaccine (A/Brisbane/59/2007). All 162 influenza A (H3N2) viruses are related to the A (H3N2) vaccine component (A/Brisbane/10/2007).
All 125 novel influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference virus selected by WHO as a potential candidate for novel influenza A (H1N1) vaccine.
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-five influenza B viruses tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 452 viruses belong to the B/Victoria lineage and are not related to the vaccine strain.
Data on antigenic characterization should be interpreted with caution given that antigenic characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference ferret antisera and results may not correlate with clinical protection against circulating viruses provided by influenza vaccination.
Annual influenza vaccination is expected to provide the best protection against those virus strains that are related to the vaccine strains, but limited to no protection may be expected when the vaccine and circulating virus strains are so different as to be from different lineages, as is seen with the two lineages of influenza B viruses. Antigenic characterization of novel influenza A (H1N1) viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with seasonal influenza vaccine.
Antiviral Resistance:

Since October 1, 2008, 975 seasonal influenza A (H1N1), 169 influenza A (H3N2), and 508 influenza B viruses have been tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir). Nine hundred eighty-one seasonal influenza A (H1N1) and 172 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine). One hundred eighty-four novel influenza A (H1N1) viruses have been tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir). One hundred forty-one novel influenza A (H1N1) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine). The results of antiviral resistance testing performed on these viruses are summarized in the table below.
<TABLE class=table border=0 cellSpacing=0 cellPadding=3 align=center><TBODY><TR><TH width=160 align=left></TH><TH width=100 noWrap align=middle>Isolates tested (n)</TH><TH width=200 colSpan=2 noWrap align=middle>Resistant Viruses,
Number (%)</TH><TH width=100 noWrap align=middle>Isolates tested (n)</TH><TH width=120 noWrap align=middle>Resistant Viruses, Number (%)</TH></TR><TR><TH width=160 align=left></TH><TH width=100 noWrap align=middle></TH><TH width=100 noWrap align=middle>Oseltamivir</TH><TH width=100 noWrap align=middle>Zanamivir</TH><TH width=100 noWrap align=middle></TH><TH width=120 noWrap align=middle>Adamantanes</TH></TR><TR><TD width=160 noWrap align=left>Seasonal Influenza A (H1N1)</TD><TD width=100 noWrap align=middle>975</TD><TD width=100 noWrap align=middle>970 (99.5%)</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>981</TD><TD width=120 noWrap align=middle>5 (0.5%)</TD></TR><TR><TD width=160 noWrap align=left>Influenza A (H3N2)</TD><TD width=100 noWrap align=middle>169</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>172</TD><TD width=120 noWrap align=middle>172 (100%)</TD></TR><TR><TD width=160 noWrap align=left>Influenza B</TD><TD width=100 noWrap align=middle>508</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>N/A*</TD><TD width=120 noWrap align=middle>N/A*</TD></TR><TR><TD width=160 noWrap align=left>Novel Influenza A (H1N1)</TD><TD width=100 noWrap align=middle>184</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>0 (0)</TD><TD width=100 noWrap align=middle>141</TD><TD width=120 noWrap align=middle>141 (100%)</TD></TR></TBODY></TABLE> <SUP>*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. </SUP>



Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with confirmed, probable or suspected cases of novel influenza A (H1N1) virus infection who are hospitalized or who are at higher risk for seasonal influenza complications. The novel influenza A (H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications, amantadine and rimantadine. Additional information on antiviral recommendations for treatment and chemoprophylaxis of novel influenza A (H1N1) infection is available at http://www.cdc.gov/h1n1flu/recommendations.htm
In areas that continue to have seasonal influenza activity, especially those with circulation of oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human influenza A (H1N1) virus infection.
Pneumonia and Influenza (P&I) Mortality Surveillance

During week 22, 6.4% of all deaths reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is below the epidemic threshold of 7.0% for week 22.
<CENTER>
picurve22.gif

View Full Screen</CENTER>Influenza-Associated Pediatric Mortality

Three influenza-associated pediatric deaths were reported to CDC during week 22 (New York City, Oklahoma, and Texas). Two of these deaths were associated with infections with novel influenza A (H1N1) viruses and one was due to seasonal influenza A (H1N1). The deaths reported this week occurred between February 15, 2009 and May 30, 2009. Since September 28, 2008, CDC has received 70 reports of influenza-associated pediatric deaths that occurred during the current influenza season, five of which were due to confirmed novel influenza A (H1N1) virus infections.
Of the 34 children who had specimens collected for bacterial culture from normally sterile sites, 14 (41.2%) were positive; Staphylococcus aureus was identified in nine (64.3%) of the 14 children. One of the three children with confirmed novel influenza A (H1N1) infection had a specimen collected from a normally sterile site; bacterial cultures were negative. Four of the S. aureus isolates were sensitive to methicillin and five were methicillin resistant. Twelve (85.7%) of the 14 children with bacterial coinfections were five years of age or older and 10 (71.4%) of the 14 children were 12 years of age or older. An increase in the number of influenza-associated pediatric deaths with bacterial coinfections was first recognized during the 2006-07 influenza season. In January 2008, interim testing and reporting recommendations were released regarding influenza and bacterial coinfections in children and are available at (http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268).
<CENTER>
IPD22_small.gif

View Full Screen</CENTER>Influenza-Associated Hospitalizations

Laboratory-confirmed influenza-associated hospitalizations are monitored in two population-based surveillance networks: the New Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).
During October 12, 2008 to May 30, 2009, the preliminary laboratory-confirmed influenza-associated hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. Because of case identification methods utilized in this study, there is a delay from the date of hospitalization to the date of report.
<CENTER>
NVSN22_small.gif

View Full Screen</CENTER>

During April 15, 2009 ? June 6, 2009, the following preliminary laboratory-confirmed overall influenza associated hospitalization rates were reported by the EIP (rates include type A, type B, and confirmed Novel H1N1):
Rates for children aged 0-23 months, 2-4 years, 5-9 years, and 10-17 years were 0.8, 0.1, 0.2, and 0.08 per 10,000, respectively. Rates for adults aged 18-29 years, 30-49 years, and = 50 years, the overall flu rates were 0.06, 0.06, and 0.1 per 10,000, respectively.
<CENTER>
EIP22_small.gif

<SUP>*This value represents an age group-specific average influenza rate from October 1 to April 30 from the 2005-06, 2006-07, and 2007-08 influenza seasons.
</SUP><SUP>**Note: The scale for the 0-23 month age group differs from other age groups. </SUP>

View Full Screen</CENTER>Outpatient Illness Surveillance:

Nationwide during week 22, 1.9% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.4%.
<CENTER>
image222.gif

View ILINet Regional Charts | View Chart Data |View Full Screen
</CENTER>


On a regional level, the percentage of outpatient visits for ILI ranged from 0.7% to 5.2%. Two of the 10 surveillance regions reported an ILI percentage above their region specific baseline (Regions I and II). ILI decreased during week 22 in eight of 10 regions compared to week 21.
Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of influenza activity.

During week 22, the following influenza activity was reported:
  • Widespread influenza activity was reported by eight states (Arizona, Connecticut, Delaware, Massachusetts, New Jersey, New York, Pennsylvania, and Rhode Island).
  • Regional influenza activity was reported by nine states (Alabama, California, Hawaii, Illinois, Maine, South Carolina, Texas, Utah, and Virginia).
  • Local influenza activity was reported by the District of Columbia, Puerto Rico, and 15 states (Georgia, Kansas, Maryland, Michigan, Minnesota, Nevada, New Hampshire, New Mexico, North Carolina, Oklahoma, Tennessee, Vermont, Washington, Wisconsin, and Wyoming).
  • Sporadic activity was reported by 17 states (Alaska, Arkansas, Florida, Idaho, Indiana, Iowa, Kentucky, Louisiana, Mississippi, Missouri, Montana, Nebraska, North Dakota, Ohio, Oregon, South Dakota, and West Virginia).
  • One state did not report (Colorado).
<OBJECT id=Banner classid=clsid:D27CDB6E-AE6D-11cf-96B8-444553540000 width=620 height=420>
























</OBJECT>
<SCRIPT type=text/javascript> var stamp = new Date() var movieurl = "/flu/weekly/smallmap/SmallFluActivity_v2.swf?c=FluMap&n=" + stamp.getTime(); var so = new SWFObject(movieurl, "Banner", "620", "420", "7"); so.write("flashALTcontent"); so.addParam("scale", "noorder"); so.addParam("allowScriptAccess","sameDomain"); so.addParam("wmode", "transparent"); so.addParam("quality", "best"); so.addParam("salign", "r"); so.addParam("type", "application/x-shockwave-flash"); </SCRIPT>
--------------------------------------------------------------------------------
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm

<SUP></SUP>
<SCRIPT type=text/javascript> <!-- function popupnr(mylink, windowname, refocus) { var mywin, href; if (typeof(mylink) == 'string') href=mylink; else href=mylink.href; mywin = window.open('', windowname, 'width=450,height=550,scrollbars=yes'); // if opened the window if ( mywin.closed || (! mywin.document.URL) || (mywin.document.URL.indexOf("about") == 0) ) mywin.location=href; else if (refocus) mywin.focus(); return false; } //--> </SCRIPT>
  • <!--
  • Page last reviewed-->
  • Page last updated June 12, 2009.
 
Re: CDC Surveillance Week 22

niman said:
2008-2009 Influenza Season Week 22 ending June 6, 2009
All data are preliminary and may change as more reports are received.


Approximately 89% of all influenza viruses being reported to CDC were novel influenza A (H1N1) viruses.
  • Page last updated June 12, 2009.
Click to expand...

The above statement is clearly false (more CDC math for the guillible). Of the influenza that was fully characterized, 9 were H1N1 seasonal flu, 22 were H3N2, 18 were influenza B, and 2071 were swine H1N1. 2071/2120 is 97.7%, which is NOT approximately 89%. Moreover, virtually all of the 315 unsubtypable will also be swine flu.

Thus, the true ratio is approximately 2386/2435 or 98.0%, so the odds are 50/1 that patients infected with influenza in the United States are infected with swine flu. The movement from 50/50 to 50/1 took just over a month. The swine H1N1 loves the heat, psuedo math notwithstanding.​
 
Re: CDC Surveillance Week 22

ILI slightly down in their graph, but not much.
Confirmed cases slightly up, but not much.

However the number of tested specimens goes down,
although the number of positives is still increasing.
That is unusual, not seen with seasonal flu
and it deranges the picture a bit.




During week 17 (April 26 - May 2, 2009), influenza activity increased in the United States.
During week 18 (May 3 - 9, 2009), influenza activity remained at approximately the same level
During week 19 (May 10 - 16, 2009), influenza activity decreased in the United States,
During week 20 (May 17 - 23, 2009), influenza activity decreased in the United States,
During week 21 (May 24 - 30, 2009), influenza activity decreased in the United States,
During week 22 (May 31 ? June 6, 2009), influenza activity decreased in the United States



attachment.php



if we assume that weeks 17,18 were deranged by hype, then we had a slow increase
from week 17 to week 21 with a peak in week 21 and now decreasing in week 22
 

Attachments

  • ili22.gif
    ili22.gif
    8 KB · Views: 0
Re: CDC Surveillance Week 22

so, why is the number of Censorflu-positives still growing ?

The positives-rate is high, they are becoming good at diagnosing
Censorflu without testing and at selecting the cases which
are likely(>40%) positive.

So despite there being fewer people presenting with ILI,
there are more positives for Censorflu.
 
Re: CDC Surveillance Week 22

gsgs said:
so, why is the number of Censorflu-positives still growing ?

The positives-rate is high, they are becoming good at diagnosing
Censorflu without testing and at selecting the cases which
are likely(>40%) positive.

So despite there being fewer people presenting with ILI,
there are more positives for Censorflu.
Click to expand...
Swine flu isn't censored. It wasn't censored in the recent Science and Nature papers which conclude that the originating strain hasn't been pinned down, but it obviously is swine derived. Moreover, teh Nature paper has teh most closley related sequences, which are from pigs in Hong Kong (but have North American flu genes and had these genes in isolates collected years ago). No one calls H1N1 swine flu Mexican flu, for reasons stated many times.

The number of samples tested is down because all states have announced that they are limiting testing and focusing on hospitlized cases. The percentage detected is going up because flu seasonal is over and seasonal flu, as well as other respiratory viruses that cause influenza like symptoms, are also down, so now the vast majority of people with real flu like symtoms have swine flu.
 
Re: CDC Surveillance Week 22

It will take at least 5 more weeks until the full effects of school closings start to show on this report:

  • Two weeks until schools close in high flu areas like Boston and New York City
  • One week lag time in this flu report
  • Two weeks for the school closings to change the flu pattern, if they do
 
You must log in or register to reply here.
Back
Top